Assembly BillFailedHealth and Safety
AB 1320: California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
What AB 1320 does, verified February 3, 2026
The bill aims to increase competition and lower prices for opioid antagonists, essential medicines in the fight against the opioid epidemic. It prohibits state agencies from awarding non-competitive contracts for the purchase or acquisition of these medicines to contractors who have entered into a multistate settlement agreement for their role in contributing to the opioid epidemic. This would make such contracts void and unenforceable. The bill applies these provisions retroactively to contracts entered into before January 1, 2026, to ensure greater accountability and transparency in the procurement of life-saving medicines.
Bill journey
✓IntroducedComplete
2In CommitteeCurrent
3First Chamber FloorPending
4Second ChamberPending
5GovernorPending
6ChapteredPending
Last action: From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. (2026-02-02)Alert me
Author and sponsors
Full contact details, staff, and committees with Connect, $15/moUnlockRecent actions7 total · showing 5
| Feb. 02, 2026 | From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. |
| Jan. 31, 2026 | Died pursuant to Art. IV, Sec. 10(c) of the Constitution. |
| Apr. 29, 2025 | In committee: Set, first hearing. Failed passage. Reconsideration granted. |
| Mar. 13, 2025 | Referred to Com. on HEALTH. |
| Feb. 24, 2025 | Read first time. |